Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)

• Company Description    Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $6.56 Daily Weekly Monthly 20 Day Moving Average: 682,147 shares Shares Outstanding: 38.82 (millions) Market Capitalization: $254.67 (millions) Beta: -0.09 52 Week High: $16.45 52 Week Low: $4.93 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -48.79% -51.29% 12 Week -48.71% -52.59% Year To Date -36.19% -43.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Design Center Place Suite 17-500 - Boston,MA 02210 USA ph: 857-520-9158 fax: - investors@entradatx.com http://www.entradatx.com

• General Corporate Information    Officers Dipal Doshi - Chief Executive Officer Kush M. Parmar - Chairman Kory Wentworth - Chief Financial Officer Gina Chapman - Director Peter S. Kim - Director Peer Information Entrada Therapeutics, Inc. (CORR.) Entrada Therapeutics, Inc. (RSPI) Entrada Therapeutics, Inc. (CGXP) Entrada Therapeutics, Inc. (BGEN) Entrada Therapeutics, Inc. (GTBP) Entrada Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29384C108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 38.82 Most Recent Split Date: (:1) Beta: -0.09 Market Capitalization: $254.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.94 Price/Cash Flow: - Price / Sales: 44.38 EPS Growth vs. Year Ago Period: -126.19% vs. Previous Quarter: -1.06% Sales Growth vs. Year Ago Period: -95.74% vs. Previous Quarter: -32.64% ROE 03/31/26 - -51.22 12/31/25 - -39.83 09/30/25 - -26.42 ROA 03/31/26 - -42.20 12/31/25 - -33.32 09/30/25 - -22.08 Current Ratio 03/31/26 - 13.90 12/31/25 - 12.52 09/30/25 - 14.08 Quick Ratio 03/31/26 - 13.90 12/31/25 - 12.53 09/30/25 - 14.08 Operating Margin 03/31/26 - -2,895.05 12/31/25 - -565.48 09/30/25 - -168.16 Net Margin 03/31/26 - -2,895.05 12/31/25 - -565.48 09/30/25 - -168.16 Pre-Tax Margin 03/31/26 - -2,878.28 12/31/25 - -561.84 09/30/25 - -169.85 Book Value 03/31/26 - 6.98 12/31/25 - 8.01 09/30/25 - 8.96 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©